News
ILMN
181.10
+2.58%
4.55
ValuEngine Weekly Market Summary And Commentary
Seeking Alpha · 3h ago
Guggenheim Maintains Buy on Illumina, Raises Price Target to $200
Benzinga · 18h ago
Roche Can Take Illumina's Crown With New Gene-Sequencing Tool -- Market Talk
Dow Jones · 20h ago
Illumina price target raised to $200 from $180 at Guggenheim
TipRanks · 21h ago
Weekly Report: what happened at ILMN last week (0622-0626)?
Weekly Report · 22h ago
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip 
Reuters · 1d ago
Insider Shake-Up: General Dynamics, Autodesk, HPE, Macy’s, Illumina
TipRanks · 2d ago
The Disinflation Trade Has A New Address: Genomics
Seeking Alpha · 3d ago
Illumina Price Target Announced at $185.00/Share by Bernstein
Dow Jones · 3d ago
Bernstein Reinstates Market Perform on Illumina, Announces $185 Price Target
Benzinga · 3d ago
Illumina resumed with a Market Perform at Bernstein
TipRanks · 3d ago
Illumina Chief Legal Officer Scott M. Davies disposes of 615 common shares worth $110,700
PUBT · 4d ago
Merck's Bio-Techne buyout put Life Sciences sector in focus: top quant-rated stocks
Seeking Alpha · 4d ago
Illumina Inc. Stock Rises 6.2%, Outperforms Market
Dow Jones · 5d ago
Illumina Is Maintained at Underweight by Barclays
Dow Jones · 5d ago
Barclays Maintains Underweight on Illumina, Raises Price Target to $145
Benzinga · 5d ago
10 large and mega-cap U.S. healthcare stocks with the strongest momentum grades
Seeking Alpha · 5d ago
ILLUMINA <ILMN.O>: BARCLAYS RAISES TARGET PRICE TO $145 FROM $122
Reuters · 5d ago
Illumina price target raised to $145 from $122 at Barclays
TipRanks · 5d ago
More
Webull provides a variety of real-time ILMN stock news. You can receive the latest news about Illumina Inc through multiple platforms. This information may help you make smarter investment decisions.
About ILMN
Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.